ChemoCentryx, Inc. Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress

Published: May 29, 2012

MOUNTAIN VIEW, Calif., May 26, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI - News), today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor of the complement anaphylatoxin receptor known as C5aR. CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the kidney. ANCA-associated renal vaculitis can lead to renal failure and a high mortality if untreated. As presented in two posters at the 49th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Paris, France, Phase I clinical trial results, supported by findings from preclinical in vivo studies, established the target dosing level for the Company's ongoing Phase II clinical trial.

Back to news